Home » EMA Safety Signal Review Prompts Tougher Risk-Management Demand
EMA Safety Signal Review Prompts Tougher Risk-Management Demand
November 11, 2013
The European Medicines Agency took the wraps off its new safety monitoring program with a request that Takeda Oncology and Seattle Genetics develop a tougher risk-management plan for the lymphoma treatment Adcetris.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor